Many studies
have shown that anxious and depressive symptoms frequently coexist
in patients seen in clinical practice.1-3 Although early
research and psychopharmacologic treatment studies tended to dintinguish
anxiety disorders from depression, emphasizing one end of the spectrum
or the other, recent developments are now reversing this trend.4
Stahl proposed three predominant points of view on how symptoms
of anxiety and depression are related.2,5
The traditional
point of view2,4 suggests that generalized symptoms of
anxiety and depression can be dichotomized into one syndrome known
as major depressive disorder (D) and another known as generalized
anxiety disorder (A). The comorbid point of view2,4,6,7
suggests a third category, namely the presence of both anxiety and
depression (DA). This has proven to be particularly true in cases
of panic disorder, obsessive compulsive disorder, and social phobia,
in which a high incidence of current or past major depressive disorder
is recognized. Depressive disorder in such cases is not seen as
being part of the anxiety disorder, but as a concomitant, comorbid
illness. Finally, the subsyndromal point of view2,4,6-8
considers that depression and anxiety can also be present to a degree
that is greater than normal but less than that required for a full
diagnostic syndrome of depression or anxiety. Thus, anxiety (a)
and depression (d) and mixed anxiety depression (da) can be subsyndromal.
Furthermore, full syndromal and subsyndromal mixtures can also occur
(eg. aD and dA).
The 10th
International Classification of Disease (ICD-10) introduced the
concept of mixed anxiety and depressive disorder in order to provide
a clinical definition for patients who present with both anxiety
and depressive symptoms of only limited number and/or intensity.9
Details of ICD-10 diagnostic guidelines and DSM-IV research criteria
of mixed anxiety and depressive disorder (MADD)10 have
been reviewed else where. Therefore, this article will review the
topics of clarification the terminology, prevalence of MADD in primary
care setting, and the process involved in diagnosing MADD.
Clarification
of the terminology
Mixed anxiety-depression
is a potentially ambiguous term11 because it is often
used to refer to different situations.
First, it refers
to symptoms of mixed anxiety-depression found in any patient. In
this sense, the abbreviation MADS is used to stand for mixed anxiety
and depressive symptoms.
Second, it
refers to the simultaneous presence or the comorbidity2,4,12,13
or the concomitant occurrence of threshold levels of two disorders
such as major depression and generalized anxiety disorder (DA) or
major depression and panic disorder (DA), or major depression and
social phobia (DA), etc.
Third, it refers
to subsyndromal4,14 or subthreshold4,15 level
of one disorder concomitant with the threshold level of another
disorder such as major depression with anxiety symptoms (Da) or
generalized anxiety disorder with depressive symptoms (Ad) or panic
disorder with depressive symptoms (Ad), etc,
Fourth, it
refers to a specific disorder according to ICD-109 or
DSM-IV10 or any specific criteria, for which the abbreviation
MADD is used to stand for mixed anxiety and depressive disorder.
Fifth, it refers
to subsyndromal mixed anxiety-depression that does not meet criteria
of ICD-10 or DSM-IV.
Finally, it
has a general meaning that includes all five groups above, which
makes it very difficult to interpret data published in various journals.
How common
is mixed anxiety-depression
Epidemiologic
studies carried out in the community have shown that subsyndromal
mixed anxiety-depression occurs in 0.8% to 2.5% in the general population.6
In a U.S. study using the DSM-III-R criteria, the 1-year prevalence
of mixed subsyndromal anxiety and depressive symptoms was found
to be 2.5%16 while other studies have demonstrated higher
rates of 5-15%.14,17,18
The DSM-IV
field trial indicated that the prevalence of subsyndromal symptoma-tology
was even higher in psychiatric outpatient clinics (12%) than in
primary care (6.5%)19 which is close to the 10% to 15%
of patients presented at an anxiety clinic in Quebec, Canada.1
Estimates of
the prevalence of mixed anxiety-depression in primary care clinical
settings may be more instructive. Roy-Byrne et al. found 5.1% of
patients with subsyndromal mixed anxiety-depressive symptoms compared
with 6.4% with generalized anxiety symptoms.14 In another
study of a much larger sample in a health maintenance organization
(HMO) setting, 5.5% of patients had subsyndromal mixed anxiety-depressive
symptoms.20
Some studies
in primary care offer data on mixed anxiety-depression and ability
to function. In the study of Ormel and his co-workers,21
40% of patients with subsyndromal anxiety and 43% with subsyndromal
mixed anxiety and depression had at least mild impairment in social
role, while 30% of patients with subsyndromal anxiety and 57% with
subsyndromal mixed anxiety and depression had at least mild impairment
in occupational role.
Rates of impairment
are significantly higher than in normals. At 1-and 3? -year follow-up,
patients with anxiety showed improvement in occupational but not
social disability while the mixed group showed improvement in both
but continued residual social disability.21
However, those
reports mentioned earlier mainly focussed on mixed anxiety-depressive
symptoms (MADS). Very few studies have been reported on a distinct
mixed anxiety and depressive disorder (MADD).
To the best
of the author, there is no epidemiologic data using the proposed
criteria for MADD in the DSM-IV appendix. However, there are at
least two papers which studied MADD in primary care setting using
ICD-10 criteria or their own operational criteria and found that
10.9% and 12.8% of psychiatric patients studied in Thailand22
and Canada23 respectively had MADD.
The
first diagram compares these two studies. The left side is the
study in a primary care clinic in Manitoba, Canada.23
Seven hundred eighty eight clinic attendees gave informed written
consent to complete the Beck depression and anxiety inventories
(BDI and BAI), and 501 of these subjects agreed to participate in
a diagnostic interview. Only 88 patients were selected for interview
on the basis of their questionnaire scores BDI or BAI more than
14, or BDI plus BAI more than 17. Ten subjects could not be interviewed
for various reasons leaving 78 subjects who received in-person diagnostic
interviews. The diagnostic interview was conducted using a version
of the structured clinical interview for DSM-III-R modified by their
research group to facilitate the efficient diagnosis of anxiety
or depressive disorders as well as MADD. They called this instrument
the SCID-FM, which stands for structured clinical interview for
DSM-III-R, Family Medicine version.
Their operational
criteria for MADD are as the following.
1. Failure
to meet any DSM-III-R diagnosis for a depressive or anxiety disorder
2. At least
10 days of either
a) Feeling
depressed or down most days, or
b) Noticeable
loss of interest in activities nearly every day
3. Consistent
presence of at least two of the remaining DSM-III-R criteria for
major depression
4. Consistent
presence of at least 3 out of 18 DSM-III-R symptoms of
generalized
anxiety disorder.
Both depressive
and anxiety symptoms in criteria 2, 3 and 4 must have at least 6
symptoms and must be nonoverlapping to meet a diagnosis of MADD.
These operational criteria for MADD correspond approximately to
the ICD-10 definition of MADD but are somewhat different from the
proposed criteria for MADD in the DSM-IV appendix which will be
pointed out later.
By using these
criteria, it was found that MADD was the most common psychiatric
disorder (12.8%) of patients interviewed together with pure anxiety
disorders (12.8%) followed by pure depressive disorders (10.7%).
Limitations
of this study are the use of 1-month duration criteria for GAD as
opposed to the standard 6-month definition. As a result some cases
diagnosed as GAD may not have lasted for 6 months and some of these
patients may have fallen into the MADD category. The second limitation
related to MADD is that their own operational definition of MADD
is different from proposed criteria in DSM-IV, as they did not exclude
persons with a prior history of mood disorders or generalized anxiety
disorder.
The study also
found that patients with MADD were more impaired than controls on
measurement of the social and family/home life subscale of the Sheehan
disability scale. However, MADD patients did not differ significantly
from depressive or anxiety disorders and impairment of MADD was
higher than in a pure anxiety group but less than in a pure depression
group.
The right side
of the diagram is the study in 4 sites of primary care setting in
the central part of Thailand.22 The sites were representative
of rural, semi-rural, urban, and suburban areas.
Eight hundred
and forty three consecutive patients visiting 4 health centres were
screened for psychiatric morbidity by the GHQ-12. Their functional
disability was simultaneously assessed by the Brief Disability Questionnaire
(BDQ). Patients with a GHQ score of 2 or more were classified as
probable psychiatric cases and those with a score of 0 or 1 as non-cases.
Four hundred and two cases were GHQ positive and these were allocated
into two groups, control and experiment with the ratio of 2:1. There
were 137 patients in the experimental group who performed the computerised
self-assessment version of the clinical interview schedule revised
(CIS-R) called the PROgrammable Questionnaire System (PROQSY) to
diagnose non-psychotic disorder in the primary care setting. Sixty
eight out of 137 subjects (49.6%) met ICD-10 criteria for non- psychotic
mental disorders. Of these patients, MADD was still found to be
the most common diagnosis (10.9%) in primary care, followed by neurasthenia
(6.0%) phobic disorders (3.4%), depression (1.6%), panic disorder
(0.3%) and generalized anxiety disorder (0.3%). It was found that
the mean BDQ score of patients with MADD (5.7) fell between depressive
patients (7.4) and patients with anxiety disorders (5.4), and all
of them were higher than the mean BDQ score of subjects with psychiatric
diagnosis (4.5, SD=3.0)
Limitations
of this study are the use of self-administered computerised assessment
to diagnose cases instead of interview by clinician and the method
of interpreting MADD which comes from exclusion of all possible
major non-psychotic disorders according to ICD-10 criteria.
However, both
studies support not only the existence but also the potential importance
of MADD among primary-care patients.
How to diagnose
MADD
The first step
in the diagnostic evaluation of mixed depressive and anxiety symptoms
is to consider potential underlying medical causes.24
There is, of course, no recipe that can be followed for a routine
workup for every patient. The extent of the diagnostic workup must
be guided by the patients medical history and review of systems.
For example, in a patient with lung cancer who had mixed anxiety-depressive
symptoms (MADS), there must be a high index of suspicion for central
nervous system tumor involvement and a diagnostic workup might well
include neuroimaging and metabolic studies such as calcium and blood
counts. In a physically healthy patient with a negative medical
review of systems, there is little cost effectiveness in any routine
laboratory screening. Medical risk factors should guide the extent
of the workup. A thorough medication history, including drug and
substance use, is critical.
The second
step involves looking for MADS caused by the direct physiological
effects of a drug of abuse (e.g. alcohol or cocaine) or the side
effects of a medication (e.g. steroid).
After ruling
out medical causes and drug or substance use, the third step is
to differentiate patients with MADS into four groups of mental disorders
according to diagnostic guidelines in ICD-109 or diagnostic
criteria in DSM-IV.10
1. Patients
with a primary Anxiety disorders with depressive symptoms (Ad) such
as panic disorder or generalized anxiety disorder or obsessive compulsive
disorder or social phobia with mild depressive symptoms or subthreshold
level of depressive disorder.
2. Patients
with a primary Depressive disorders with anxiety symptoms (aD) such
as major depression, dysthymic disorder with mild anxiety symptoms
or subthreshold level of anxiety disorder.
3. Patients
with both primary diagnoses of Anxiety disorders and Depressive
disorders (AD) such as major depression comorbid with panic disorder.
4. Patients
with subsyndromal manifestation of both anxiety and depression (ad)
and having symptoms fulfilling the criteria of MADD according to
ICD-10 or DSM-IV.
Some clinicians
suggest to differentiating other mental disorders such as somatoform
disorders and personality disorders. Among the latter, avoidant,
dependent and obsessive-compulsive personality disorders may have
symptoms that resemble those of mixed anxiety-depressive disorder.25
Therefore the
algorithm in diagram 2 is suggested
by the author as a decision tree for differential diagnosis of patients
with MADS.
Conclusion
At this time
MADD is only included as a provisional category in the DSM-IV; it
is designated as a separate diagnostic category in ICD-10. Epidemiologic
studies support the existence and also the potential importance
of MADD among primary care patients. Patients with MADD rated their
disability as being comparable to that of patients with anxiety
or depressive disorders. Although some studies support the high
prevalence rate of MADD among primary-care settings, making it eligible
to be a distinct disease entity, further longitudinal studies are
needed to map the temporal stability of MADD, i.e., that is whether
or not MADD evolves into full-blown anxiety or depressive disorders
within a specific time frame. If such were the case, then MADD would
be best conceptualized as a transitional state rather than a disorder
in need of a new diagnostic rubric. Other issues that need to be
addressed include: the determination of how (and if) to treat, and
whether or not treatment diminishes the disability of patients.
References
1.Boulenger JP, Fournier M,
Rosales D, Lavallee YJ. Mixed anxiety and depression : from theory
to practice. J Clin Psychiatry 1997;58 (suppl 8):27-34.
2. Stahl SM. Mixed anxiety
and depression : clinical implications. J Clin Psychiatry 1993;54:
(suppl 1):33-8.
3. Downing RW, Rickels K. Mixed
anxiety - depression : fact or myth ? Arch Gen Psychiatry 1974;30:312-7.
4. Stahl SM. Mixed depression
and anxiety : serotonin 1A receptors as a common pharmacologic link.
J Clin Psychiatry 1997;58 (suppl 8):20-36.
5. Stahl SM. Essential Psychopharmacology.
New York : Cambridge University Press, 1996.
6. Wittichen HU, Essau CA.
Comorbidity and mixed anxiety-depressive disorders : is there epidemiologic
evidence ? J Clin Psychiatry 1993;54 (suppl 1):9-15.
7. Brown TA, Barlow DH. Comorbidity
among anxiety disorders : implication for treatment and DSM-IV.
Consult Clin Psychol 1992;60:835-44.
8. Angst J, Merikangas KR,
Preisig M. Subthreshold syndromes of depression and anxiety in the
community. J Clin Psychiatry 1997;58 (suppl 8):6-10.
9. International Classification
of Diseases. The ICD-10 Classification of Mental and Behavioural
Disorders. Clinical Descriptions and Diagnostic Guidelines. Geneva
: World Health Organization;1992.
10. American Psychiatric Association.
Diagnostic and Statistical Manual of Mental Disorders. 4th
and Washington, DC : American Psychiatric Press;1994:723-5.
11. Goldberg RJ. Diagnostic
dilemmas presented by patients with anxiety and depression. Am J
Med 1995;98(3):278-84.
12. Dunner DL. Anxiety and
panic : relationship to depression and cardiac disorders. Psychosomatics
1985;26 (suppl 11):18-21.
13. Henninger GR. A biologic
perspective on co-morbidity of a major depressive disorder and panic
disorder. In : Maser JD, Cloninger CR, eds. Co-morbidity of Mood
and
Anxiety Disorders. Washington,
DC : American Psychiatric Press. 1990:381-401.
14. Roy-Byrne P, Katon W, Broadhead
WE, et al. Subsyndromal (mixed) anxiety-depression in primary
care. J Gen Intern Med 1994;9:507-12.
15. Angst J, Merikangas KR,
Preisig M. Subthreshold syndromes of depression and anxiety in the
community. J Clin Psychiatry 1997;58 (suppl 8):6-10.
16. Judd LL, Rapaport MH, Paulus
MP, et al. Subsyndromal symptomatic depression : a new mood disorder
? J Clin Psychiatry1994;55 (suppl 4):18-28.
17. Von Korff M, Shapiro S,
Burke JD, et al. Anxiety and depression in a primary care clinic.
Arch Gen Psychiatry 1987;44:152-6.
18. Barrett JE, Barrett JA,
Oxman TE, et al. The prevalence of psychiatric disorders in a primary
care practice. Arch Gen Psychiatry 1988;45:1100-6.
19. Zinbarg RE, Barlow DH,
Liebowitz M, et al. The DSM-IV field trial for mixed anxiety-depression.
Am J Psychiatry 1994;151:1153-62.
20. Fifer SK, Mathias SD, Patrick
DL, et al. Untreated anxiety among adult primary care patients in
health maintenance organization. Arch Gen Psychiatry 1994;51:740-50.
21. Ormel J, Oldehinkel T,
Brilman E, et al. Outcome of depression and anxiety in primary care
: a three-wave 3? year study of psychopathology and disability.
Arch
Gen Psychiatry 1993;50:759-66.
22. Silpakit C. A study of
common mental disorders in primary care in Thailand. Thesis submitted
for the degree of Doctor of Philosophy to the Faculty of Medicine,
University of London. December
1997.
23. Stein MB, Kirk P, Prabhu
V, et al. Mixed anxiety-depression in a primary-care clinic. J Affect
Disord 1995;34:79-84.
24. Goldberg RJ. Diagnostic
dilemmas presented by patients with anxiety and depression. Am J
Med 1995;98:278-84.